Investigation on efficacy and safety of rivastigmin patch in patients switched from donepezil with mild to moderate Alzheimer's disease

Investigation on efficacy and safety of rivastigmin patch in patients switched from donepezil with mild to moderate Alzheimer's disease - Efficacy and safety of rivastigmin patch in patients switched from donepezil

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010842

Enrollment

100

Registered

2013-05-30

Start date

2013-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 1) who are mild to moderate Alzheimer's disease, 2) who take donepezil 3 to 5mg/day more than 3 months, 3) who show a poor response to donepezil, poor medication adherence due to dysphagia or adverse effects, or hope for switch to transdermal patch, and 4) who understand the points of this study and give informed-consent in literature.

Exclusion criteria

Exclusion criteria: 1)Patients who correspond to the administration contraindication of the objective drug 2)Patients inadequate for the study

Design outcomes

Primary

Measure	Time frame
Changes from baseline at week 24 on Clinical Global Impression of Change(CGIC)	—

Secondary

Measure	Time frame
Changes from baseline at week 24 on caregiver-rated modified Crichton scale(CMCS)	—

Countries

Japan

Contacts

Public ContactSonoko Danjo

Kagawa University School of Medicine Department of Neuropsychiatry

sdanjo@med.kagawa-u.ac.jp0878912167

Outcome results